Matthew B. Klein's Insider Trades & SAST Disclosures
Matthew B. Klein's most recent trade in ClearPoint Neuro Inc was a trade of 21,093 Common Stock done . Disclosure was reported to the exchange on May 16, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Matthew B. Klein.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ClearPoint Neuro Inc | Matthew B. Klein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2025 | 21,093 | 50,518 (0%) | 0% | - | Common Stock | |
| ClearPoint Neuro Inc | Matthew B. Klein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2025 | 21,093 | 0 | - | - | Restricted Stock Units | |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 48.74 per share. | 22 Apr 2025 | 2,804 | 273,234 (0%) | 0% | 48.7 | 136,656 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 50.10 per share. | 19 Feb 2025 | 3,897 | 279,933 (0%) | 0% | 50.1 | 195,224 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 50.12 per share. | 19 Feb 2025 | 3,895 | 276,038 (0%) | 0% | 50.1 | 195,233 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 44.50 per share. | 07 Jan 2025 | 2,402 | 283,830 (0%) | 0% | 44.5 | 106,889 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 45.34 per share. | 07 Jan 2025 | 2,142 | 286,232 (0%) | 0% | 45.3 | 97,118 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 70,000 | 288,374 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 45.16 per share. | 31 Dec 2024 | 8,279 | 217,528 (0%) | 0% | 45.2 | 373,880 | Common Stock |
| ClearPoint Neuro Inc | Matthew B. Klein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 21,093 | 21,093 | - | - | Restricted Stock Units | |
| ClearPoint Neuro Inc | Matthew B. Klein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 17,153 | 0 | - | - | Restricted Stock Units | |
| ClearPoint Neuro Inc | Matthew B. Klein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 17,153 | 29,425 (0%) | 0% | - | Common Stock | |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 24.89 per share. | 19 Apr 2024 | 3,361 | 225,807 (0%) | 0% | 24.9 | 83,669 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 25.13 per share. | 17 Apr 2024 | 1,307 | 229,168 (0%) | 0% | 25.1 | 32,851 | Common Stock |
| PTC Therapeutics Inc | Klein Matthew B. | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 70,000 | 230,475 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Klein Matthew B. | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 29.01 per share. | 08 Jan 2024 | 5,443 | 160,475 (0%) | 0% | 29.0 | 157,928 | Common Stock |
| PTC Therapeutics Inc | B. Matthew Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 28.64 per share. | 08 Jan 2024 | 2,237 | 165,918 (0%) | 0% | 28.6 | 64,068 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 27.15 per share. | 05 Jan 2024 | 10,107 | 168,155 (0%) | 0% | 27.1 | 274,393 | Common Stock |
| PTC Therapeutics Inc | Matthew Klein B. | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Dec 2023 | 75,000 | 177,961 (0%) | 0% | 0 | Common Stock | |
| ClearPoint Neuro Inc | Matthew B. Klein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 17,153 | 17,153 | - | - | Restricted Stock Units | |
| PTC Therapeutics Inc | Matthew B. Klein | CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Apr 2023 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Matthew B. Klein | CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Apr 2023 | 26,000 | 103,856 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Matthew B. Klein | CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 52.04 per share. | 18 Apr 2023 | 1,211 | 102,645 (0%) | 0% | 52.0 | 63,025 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 42.93 per share. | 10 Jan 2023 | 2,273 | 80,100 (0%) | 0% | 42.9 | 97,586 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 44.36 per share. | 10 Jan 2023 | 2,244 | 77,856 (0%) | 0% | 44.4 | 99,543 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 41.66 per share. | 09 Jan 2023 | 731 | 82,373 (0%) | 0% | 41.7 | 30,451 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Matthew B. Klein | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 26,000 | 83,104 (0%) | 0% | 0 | Common Stock | |
| ClearPoint Neuro Inc | Matthew B. Klein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 9,269 | 12,272 (0%) | 0% | 0 | Common Stock | |
| ClearPoint Neuro Inc | Matthew B. Klein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 6,179 | 6,179 | - | - | Stock Options (right to buy) | |
| PTC Therapeutics Inc | Matthew B. Klein | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 42.52 per share. | 19 Apr 2022 | 897 | 56,564 (0%) | 0% | 42.5 | 38,136 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 52,500 | 52,500 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Matthew B. Klein | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Matthew B. Klein | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 21,000 | 37,461 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Matthew B. Klein | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 20,000 | 57,461 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Matthew B. Klein | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 38.53 per share. | 07 Jan 2022 | 775 | 16,461 (0%) | 0% | 38.5 | 29,857 | Common Stock |
| ClearPoint Neuro Inc | Matthew B. Klein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2021 | 6,006 | 6,006 | - | - | Stock Options (right to buy) | |
| ClearPoint Neuro Inc | Matthew B. Klein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2021 | 3,003 | 3,003 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 46.58 per share. | 19 Apr 2021 | 1,444 | 17,006 (0%) | 0% | 46.6 | 67,264 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 48.17 per share. | 19 Apr 2021 | 859 | 18,450 (0%) | 0% | 48.2 | 41,376 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 47.92 per share. | 19 Apr 2021 | 197 | 16,809 (0%) | 0% | 47.9 | 9,440 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 69.09 per share. | 15 Jan 2021 | 4,300 | 19,309 (0%) | 0% | 69.1 | 297,078 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.98 per share. | 15 Jan 2021 | 4,300 | 23,609 (0%) | 0% | 39.0 | 167,614 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2021 | 4,300 | 86,314 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.98 per share. | 08 Jan 2021 | 5,500 | 24,809 (0%) | 0% | 39.0 | 214,390 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2021 | 5,500 | 90,614 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 69.48 per share. | 08 Jan 2021 | 4,000 | 20,809 (0%) | 0% | 69.5 | 277,924 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 70.32 per share. | 08 Jan 2021 | 1,500 | 19,309 (0%) | 0% | 70.3 | 105,486 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2021 | 52,500 | 52,500 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2021 | 9,000 | 19,309 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2021 | 3,886 | 96,114 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.98 per share. | 06 Jan 2021 | 3,886 | 23,195 (0%) | 0% | 39.0 | 151,476 | Common Stock |
| PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 68.98 per share. | 06 Jan 2021 | 3,886 | 19,309 (0%) | 0% | 69.0 | 268,056 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges